- Home
- GLPG vs ADUS Comparison
GLPG vs ADUS Comparison
Compare GLPG & ADUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLPG
- ADUS
- Stock Information
- Founded
- GLPG 1999
- ADUS 1979
- Country
- GLPG Belgium
- ADUS United States
- Employees
- GLPG N/A
- ADUS N/A
- Industry
- GLPG Biotechnology: Pharmaceutical Preparations
- ADUS Medical/Nursing Services
- Sector
- GLPG Health Care
- ADUS Health Care
- Exchange
- GLPG Nasdaq
- ADUS Nasdaq
- Market Cap
- GLPG 2.1B
- ADUS 2.1B
- IPO Year
- GLPG 2005
- ADUS 2009
- Fundamental
- Price
- GLPG $32.26
- ADUS $108.10
- Analyst Decision
- GLPG Sell
- ADUS Buy
- Analyst Count
- GLPG 4
- ADUS 12
- Target Price
- GLPG $25.33
- ADUS $140.58
- AVG Volume (30 Days)
- GLPG 168.5K
- ADUS 119.5K
- Earning Date
- GLPG 10-29-2025
- ADUS 11-03-2025
- Dividend Yield
- GLPG N/A
- ADUS N/A
- EPS Growth
- GLPG N/A
- ADUS 7.74
- EPS
- GLPG N/A
- ADUS 4.52
- Revenue
- GLPG $323,674,692.00
- ADUS $1,274,082,000.00
- Revenue This Year
- GLPG N/A
- ADUS $24.29
- Revenue Next Year
- GLPG N/A
- ADUS $6.83
- P/E Ratio
- GLPG N/A
- ADUS $23.95
- Revenue Growth
- GLPG 5.43
- ADUS 14.29
- 52 Week Low
- GLPG $22.36
- ADUS $88.96
- 52 Week High
- GLPG $33.86
- ADUS $136.72
- Technical
- Relative Strength Index (RSI)
- GLPG 51.29
- ADUS 39.87
- Support Level
- GLPG $31.49
- ADUS $110.05
- Resistance Level
- GLPG $33.63
- ADUS $113.85
- Average True Range (ATR)
- GLPG 0.66
- ADUS 2.99
- MACD
- GLPG -0.06
- ADUS -0.80
- Stochastic Oscillator
- GLPG 50.18
- ADUS 4.81
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, mainly to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are medical in nature to those individuals who may require assistance during an illness or after surgery.